The world is getting fatter – and with no easy solution to obesity in sight, investing in healthcare providers and food and drink makers could bring big gains, says Jonathan Compton.
Recent articles AstraZeneca PLC
Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
The US government has issued new rules making it harder for American companies to cut their tax bill by relocating their headquarters.
A new kind of cancer therapy could make a big difference to survival rates – and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
More and more American businesses are snapping up companies in low-tax countries to make that their official home. British companies are in their sights. Simon Wilson reports.
US drugs giant Pfizer’s attempt to takeover AstraZeneca has come to a dead-end.
The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
As the head of US pharma giant Pfizer, Ian Read has led the takeover bid for Britain’s AstraZeneca. But is the British-born boss driven by revenge?
Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.